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IntroductIon
CRISPR (pronounced “crisper”) and its therapeutic 
use in human cell lines is revolutionising biomedical 
research. In particular, this is because CRISPR makes 
it straightforward to edit or inactivate genes in a cell 
line. It also simplifies the approach of creating animal 
models that are then used to explore diseases. Indeed, 
research work, which took months or years, can now be 
completed in weeks.
the Key Players
“CRISPR” stands for “clusters of regularly interspaced short 
palindromic repeat”. In detail, CRISPR is a bacterial DNA 
region made up of two specialised characteristics: (i) nucleotide 
repeats that are distributed throughout the CRISPR region, 
and (ii) spacers, bits of DNA that are interspersed among the 
nucleotide repeats. In general, the spacers are taken from viruses 
that have attacked the bacteria. Indeed, spacers are used as a bank 
of memories, therefore allowing bacteria to recognise viruses and 
fight off future attacks.
That CRISPR provides acquired resistance against viruses in 
prokaryotes was demonstrated over a decade ago.1 Here, researchers 
used the Streptococcus thermophilus bacterium, found in yoghurt 
and other dairy products, as their model. Barrangou et al. showed 
that after a virus attacks a bacterium, new spacers are introduced into 
the CRISPR region. In addition, by taking out the spacers or putting 
in new viral DNA sequences, the researchers were able to change 
the resistance of the bacterium against a particular virus. It was thus 
confirmed that CRISPRs have a role in the regulation of the bacterial 
immune system. Indeed, after introducing a spacer, a subsequent 
virus attack causes a portion of the CRISPR to be transcribed into 
crRNA, or CRISPR RNA. In this case, the CRISPR template produces 
a complementary sequence of RNA, with each crRNA consisting of a 
nucleotide repeat and a spacer portion.2
In order to stop foreign attacks, bacteria use CRISPR RNA and Cas 
proteins, including Cas9. Cas9 is an enzyme that cuts foreign DNA. It first 
binds to two RNA molecules: the crRNA, and another one called tracrRNA, 
or trans-activating crRNA. Both RNAs then guide Cas9 to the cleavage 
target site. Cas9, using two separate domains on its structure, cuts both 
strands of the double helix, resulting in a double strand break.2 Cas9 does not 
cut wherever it wants in the genome. Instead, there is a built-in mechanism 
involving short tags known as PAMs (“protospacer adjacent motifs”): if Cas9 
does not recognise a PAM next to its target site, it does not cut.
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abstract
CRISPR-Cas9 is a powerful and simple tool for 
editing genomes. It allows researchers to alter 
DNA sequences and gene function. Its potential 
applications include correcting genetic defects 
and treating and preventing the spread of diseases. 
In China, clinical human trials using CRISPR-Cas9 
are now in progress.
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GenoMe edItInG tool
Genomic DNA holds instructions for all living things. CRISPR-
Cas9 provides the means to alter these instructions. It does this 
through a break or a cut in the DNA therefore circumventing 
the repair mechanisms and introducing the alterations. It was 
this knowledge that fuelled the spiralling interest in CRISPR-
Cas9. In principle, the revolution began in 2012 with two 
research papers describing how the bacterial CRISPR-Cas9 can 
be transformed into a simple genome-editing tool. Jinek et al.3 
and Gasiunas et al.4 concluded that Cas9 could cut any DNA 
region if the nucleotide sequence of the crRNA is changed. Jinek 
et al. went further and fused crRNA and tracrRNA to create a 
single guide RNA (gRNA). Overall, genome editing requires the 
Cas9 protein and a gRNA.
Operationally, a stretch of 20 base pairs that matches the 
gene to be edited is designed. Subsequently, an RNA molecule 
that is complementary to the 20 bp stretch is constructed. Just 
like a pair of scissors, Cas9 and the RNA will then cut the DNA. 
In the end, the cell’s natural repair mechanisms will work (e.g. 
through non-homologous end joining, or NHEJ) to introduce 
the changes in the genome.
clInIcal aPPlIcatIons
It was a matter of time until the bacterial CRISPR-Cas9 was 
used in a clinical setting.5 So far, it has been used to ameliorate 
muscle function in mice with Duchenne muscular dystrophy.6 
In particular, using CRISPR, researchers deleted the defective 
gene, allowing the mice to produce one of the main proteins in 
the muscles. CRISPR is also being exploited to treat HIV,7 since 
it can attack multiple regions of the viral DNA, therefore making 
the development of virus resistance harder. In turn, this can 
decrease the chance of viral escape and resistance to treatment. 
In the field of cancer, CRISPR is being applied to turn on and 
off genes implicated in the development of cancer, to inspect 
the protein domains involved in cancer, and also, to evaluate 
the drug targets.8
In vitro and animal models of human disease have also 
demonstrated that CRISPR-Cas9 can be effective in the 
correction of genetic defects, thus paving the way for clinical 
therapeutic applications in humans. Yuan et al.,9 for example, 
investigated the role of αA-crystallin in rabbits. αA-crystallin 
increases cellular stress tolerance and prevents precipitation of 
denatured proteins.10 It is these functions that maintain eye lens 
transparency and prevent cataracts.11 Yuan et al. demonstrate 
that mutations in αA-crystallin are linked to the formation 
of cataracts. In detail, it was shown that a CRISPR-Cas9 
mutation of αA-crystallin causes congenital cataracts, failed 
differentiation of lens fibres, microphthalmia, and obscurity. 
In light of this, further investigations should pursue the 
association between mutations in the αA-crystallin gene 
and congenital cataracts in humans.
CRISPR-Cas9 is also being used to understand cystic 
fibrosis, an autosomal recessive, chronic, genetic disease 
of the lung caused by mutations in the cystic fibrosis 
transmembrane regulator (CFTR). Sanz et al.,12 for 
instance, describe an efficient method for editing three 
different and rare CFTR mutations, which together account for 
3% of patients suffering from cystic fibrosis. In a similar method, 
Schwank et al.13 used CRISPR-Cas9 to correct the CFTR locus 
through homologous recombination in intestinal stem cell 
organoids of patients.
In addition to cataracts and cystic fibrosis, CRISPR-Cas9 
studies have also been carried out on Fanconi anaemia,14 hearing 
loss,15 haemophilia,16 leishmaniasis17 and malaria.18 For example, 
hearing loss affects about 1 in 500 newborns. It is known that 
genetic deafness is often due to mutations of the inner ear genes. 
Using CRISPR-Cas9, the roles of these genes can be studied 
through the disruption of normal gene alleles via the NHEJ 
mechanism. In particular for genetic hearing loss, CRISPR-Cas9 
can disrupt mutations through NHEJ, or repair mutations via 
homology-directed-repair (HDR), both of which could restore 
hearing. Zou et al.15 have shown that genome editing is an 
efficient tool in the mammalian inner ear in vivo.
In situ genome editing has also resulted in successful 
correction of haemophilia, an X-linked genetic bleeding 
disorder due to a lack in coagulator factor IX (haemophilia B). 
In the human F9 gene, Guan et al.16 identified a new mutation 
(Y371D) in haemophilia B. Using CRISPR-Cas9 to generate 
transgenic mice, they confirmed that this novel mutation 
results in severe haemophilia. Guan et al. proceeded to develop 
therapeutic strategies targeting this mutation. 
In regard to the parasitic Leishmania donovani that causes 
leishmaniasis disease, Zhang et al.17 exploited the CRISPR-Cas9 
tool to specifically mutate the parasitic genome. In this case, 
high-throughput functional analysis can be used to understand 
its functional genes, thus promoting the discovery of future 
therapeutic strategies. In a similar approach, but for a different 
parasite, Hammond et al.18 used CRISPR-Cas9 to target female 
reproduction in the malaria mosquito vector Anopheles gambiae. 
In addition, in the agricultural and food industries, CRISPR-
Cas9 has been applied to vaccinate industrial cultures (e.g. for 
yoghurt) against viruses.19 Phage infection of starter cultures 
is a widespread and significant problem in the dairy industry. 
The process of applying CRISPR-Cas9 is simply to select those 
bacterial strains that make the best yogurt, expose them to 
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phages and screen for strains that become naturally vaccinated against the phages. This 
process is repeated until you end up with a strain that is immune to a diversity of common 
phages. In view of the fact that this entire process takes on average only a few weeks, 
many people have possibly unknowingly consumed a product that has actually been 
manufactured using CRISPR-enhanced starter cultures!
In general, the CRISPR genome editing revolution is advancing at an astounding 
pace. In China, for instance, 20 clinical human trials are now in progress, one of 
which will use CRISPR, for the first time ever, to edit cells inside the body. In doing 
so, the aim is to prevent cervical cancers by targeting the human papillomavirus 
(HPV) genes that cause the tumour to grow. This HPV trial is expected to break new 
ground. Instead of editing cells outside the body, a gel that contains DNA coding 
for CRISPR is applied to the cervix. CRISPR should leave the DNA of normal cells 
untouched, however, it should destroy cells infected with HPV, thus stopping them 
from turning cancerous.
conclusIon
Overall, the robustness and simplicity of the CRISPR-Cas9 genome editing 
in human cells and model organisms such as mice and primates make it a 
promising tool in clinical research. However, it is not without its drawbacks. 
Indeed, if the DNA is cut at sites other than the intended target, unintended 
mutations are introduced. CRISPR has also raised questions about the research 
ethics of human genome editing, especially in embryos and gametes, since 
these can be passed on to subsequent generations. In spite of this, with the 
progress seen to date, it is clear that this is just the beginning. 
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